KR20050033734A - 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 - Google Patents
다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 Download PDFInfo
- Publication number
- KR20050033734A KR20050033734A KR1020030069582A KR20030069582A KR20050033734A KR 20050033734 A KR20050033734 A KR 20050033734A KR 1020030069582 A KR1020030069582 A KR 1020030069582A KR 20030069582 A KR20030069582 A KR 20030069582A KR 20050033734 A KR20050033734 A KR 20050033734A
- Authority
- KR
- South Korea
- Prior art keywords
- dimethoxy
- phenyl
- ethyl
- tetrazol
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims (9)
- 하기 화학식 1의 테트라졸 유도체 또는 이의 약학적으로 허용가능한 염:화학식 1상기 식에서,R1은 비치환되거나 치환된 아릴, 헤테로아릴, 아크릴아릴, 아크릴헤테로아릴, 헤테로시클로알케닐 또는 카보시클로그룹이고, 이 때 치환체는 C1-C5 알킬, 하이드록시, C1-C5 알콕시, 할로겐, 트리플루오로메틸, 니트로 또는 아미노이며;R2 내지 R11은 각각 독립적으로 수소, 하이드록시, 할로겐, 니트로, C1-C 5 알킬 또는 알콕시이고, 이 때, R6 및 R11은 연결되어 4 내지 8원 고리를 형성할 수 있으며;m 및 n은 각각 독립적으로 0 내지 4 범위의 정수이고;X 는 CH2, 산소 또는 황원자이다.
- 제 1 항에 있어서,R1이 비치환되거나 치환된 페닐, 피리딘, 피리미딘, 피라진, 퀴놀린, 이소퀴놀린, 퀴나졸린, 퀴녹살린, 피라졸, 이미다졸, 트리아졸, 테트라졸, 옥사졸, 티아졸, 옥사디아졸, 티아디아졸, 벤즈이미다졸, 벤즈티아졸, 벤즈옥사졸, 크로몬, 퀴놀론, 쿠말릭, 시나믹 또는 퀴놀린아크릴(이 때, 치환체는 C1-C5 알킬, 하이드록시, C1 -C5 알콕시, 할로겐, 트리플루오로메틸, 니트로 또는 아미노임)임을 특징으로 하는 테트라졸 유도체 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,퀴놀린-3-카복실산[2-(2-4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴놀린-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,이소퀴놀린-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴놀린-8-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,이소퀴놀린-1-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴놀린-4-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,4-메톡시-퀴놀린-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴녹살린-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,피리딘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-니코틴아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-이소니코틴아미드,피라진-2-카복실산[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-벤즈아미드,나프탈렌-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-2-플루오로-벤즈아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-3-플루오로-벤즈아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-4-플루오로-벤즈아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-3,4-디플루오로-벤즈아미드,티오펜-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퓨란-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,4-옥소-4H-크로멘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,6-메틸-4-옥소-4H-크로멘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,6-메틸-4-옥소-4H-크로멘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,5-하이드록시-4-옥소-4H-크로멘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,5-메톡시-4-옥소-4H-크로멘-2-카복실산[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,6-플루오로-4-옥소-4H-크로멘-2-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,6-브로모-4-옥소-4H-크로멘-2-카복실산[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,시놀린-4-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,4-옥소-4H-크로멘-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴놀린-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디플루오로-페닐]-아미드,퀴놀린-3-카복실산 [2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸설파닐]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-아미드,퀴놀린-3-카르복실산 2-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일 에틸)-2H-테트라졸-5-일]-4,5-디메톡시-페닐-아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-3-페닐-아크릴아미드,N-[2-(2-{4-[2-(6,7-디메톡시-3,4-디하이드로-1H-이소퀴놀린-2-일)-에틸]-페닐}-2H-테트라졸-5-일)-4,5-디메톡시-페닐]-3-퀴놀린-3-일-아크릴아미드 및4-옥소-4H-크로멘-2-카르복실산 (2-{2-[4-(2-{[2-(3,4-디메톡시-페닐)-에틸]-메틸-아미노}-에틸)-페닐]-2H-테트라졸-5-일}-4,5-디메톡시-페닐)-아미드로 이루어진 군중에서 선택된 것을 특징으로 하는 테트라졸 유도체 또는 이의 약학적으로 허용가능한 염.
- i) 화학식 5의 히드라존 화합물과 화학식 6의 디아조늄염 화합물을 염기 존재하에서 고리화 반응시켜 화학식 4의 니트로페닐테트라졸 화합물을 제조하고,ii) 화학식 4의 화합물을 금속 촉매 존재하에 수소화 반응시켜 화학식 2의 아미노페닐테트라졸 화합물로 전환시킨 후,iii) 화학식 2의 화합물을 축합제 또는 염기 존재하에 화학식 3의 카복실산 또는 아실할라이드 화합물과 아실화 반응시키는 것을 포함하는, 제 1 항에 따른 화학식 1의 테트라졸 유도체의 제조방법:상기 식에서, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, m, n 및 X는 제 1 항에서 정의한 바와 같고, R'는 OH, Cl 또는 Br이고, L은 벤질 또는 톨릴이다.
- 제 4 항에 있어서,화학식 5의 화합물을, 화학식 7의 니트로벤즈알데히드 화합물을 톨루엔설포닐클로라이드 또는 벤젠설포닐클로라이드와 반응시킴으로써 제조하는 것을 특징으로 하는 방법:화학식 5상기 식에서, R2, R3, R4 및 R5는 제 1 항에서 정의한 바와 같고, L은 벤질 또는 톨릴이다.
- 제 4 항에 있어서,화학식 6의 디아조늄염 화합물을,a) 화학식 10의 니트로 화합물과 화학식 11의 아민 화합물을 염기 존재하에 반응시켜 화학식 9의 니트로 화합물을 제조하고,b) 이를 금속 촉매하에서 수소화 반응시켜 화학식 8의 아민 화합물로 전환시킨 후,c) 이를 소디움 나이트리트 및 염산과 반응시킴으로써 제조하는 것을 특징으로 하는 방법:화학식 6상기 식에서, R6, R7, R8, R9, R10, R11, m, n 및 X는 제 1 항에서 정의한 바와 같고, R''는 OH, Cl 또는 Br이고, L은 벤질 또는 톨릴이다.
- 활성성분으로서 제 1 항에 따른 화학식 1의 테트라졸 유도체 화합물 또는 이의 약학적으로 허용가능한 염 및 부형제를 포함하는, p-당단백질 저해용 약학 조성물.
- 제 7 항에 있어서,항암제를 추가로 포함함을 특징으로 하는 약학 조성물.
- 제 8 항에 있어서,항암제가 파클리탁셀 (paclitaxel), 도세탁셀 (docetaxel), 빈크리스틴 (vincristine), 빈블라스틴 (vinblastine), 빈노렐빈 (vinorelbin), 다우노마이신 (daunomycin), 독소루비신 (doxorubicin), 토포테칸 (topotecan), 이리노테칸 (irinotecan), 악티노마이신 (actinomycin) 및 에토포시드 (etopocid)로 이루어진 군 중에서 선택됨을 특징으로 하는 약학 조성물.
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030069582A KR100557093B1 (ko) | 2003-10-07 | 2003-10-07 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
PCT/KR2004/002550 WO2005033097A1 (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
US10/574,098 US7625926B2 (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
JP2006532094A JP4481992B2 (ja) | 2003-10-07 | 2004-10-06 | P−糖蛋白質阻害剤、これを製造する方法およびこれを含む医薬組成物 |
PT04774778T PT1678162E (pt) | 2003-10-07 | 2004-10-06 | Inibidor de p-glicoproteína, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
RU2006114427/04A RU2317985C1 (ru) | 2003-10-07 | 2004-10-06 | Соединения, способ их получения и фармацевтическая композиция на их основе |
AU2004277475A AU2004277475B2 (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
NZ546257A NZ546257A (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
CN2004800293562A CN1863795B (zh) | 2003-10-07 | 2004-10-06 | P-糖蛋白抑制剂,其制备方法和包括该抑制剂的药物组合物 |
MXPA06003803A MXPA06003803A (es) | 2003-10-07 | 2004-10-06 | Inhibidor de p-glicoproteina, metodo para preparar el mismo y composicion farmaceutica que comprende el mismo. |
SI200431434T SI1678162T1 (sl) | 2003-10-07 | 2004-10-06 | Inhibitor p-glikoproteina, postopek priprave le-tega in farmacevtski sestavek, ki ga vsebuje |
DK04774778.7T DK1678162T3 (da) | 2003-10-07 | 2004-10-06 | P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne |
DE602004026903T DE602004026903D1 (de) | 2003-10-07 | 2004-10-06 | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält |
AT04774778T ATE466008T1 (de) | 2003-10-07 | 2004-10-06 | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält |
BRPI0415053A BRPI0415053B8 (pt) | 2003-10-07 | 2004-10-06 | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo |
ES04774778T ES2342290T3 (es) | 2003-10-07 | 2004-10-06 | Inhibidor de la glicoproteina p, metodo para su preparacion y composicion farmaceutica que comprende dicho inhibidor. |
CA002541301A CA2541301C (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
PL04774778T PL1678162T3 (pl) | 2003-10-07 | 2004-10-06 | Inhibitor glikoproteiny P, metoda jego wytwarzania i kompozycja farmaceutyczna go zawierająca |
EP04774778A EP1678162B1 (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
IL174665A IL174665A (en) | 2003-10-07 | 2006-03-30 | Heterocyclic compounds that act as P-glycoprotein inhibitors Methods of manufacture and pharmaceutical preparations containing them |
ZA200603538A ZA200603538B (en) | 2003-10-07 | 2006-05-04 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
NO20062019A NO336127B1 (no) | 2003-10-07 | 2006-05-05 | P-glykoproteininhibitor, fremgangsmåter for fremstilling av denne samt farmasøytisk preparat omfattende den samme |
HK07103870.2A HK1096399A1 (en) | 2003-10-07 | 2007-04-13 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p- |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030069582A KR100557093B1 (ko) | 2003-10-07 | 2003-10-07 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050033734A true KR20050033734A (ko) | 2005-04-13 |
KR100557093B1 KR100557093B1 (ko) | 2006-03-03 |
Family
ID=36500896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030069582A KR100557093B1 (ko) | 2003-10-07 | 2003-10-07 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7625926B2 (ko) |
EP (1) | EP1678162B1 (ko) |
JP (1) | JP4481992B2 (ko) |
KR (1) | KR100557093B1 (ko) |
CN (1) | CN1863795B (ko) |
AT (1) | ATE466008T1 (ko) |
AU (1) | AU2004277475B2 (ko) |
BR (1) | BRPI0415053B8 (ko) |
CA (1) | CA2541301C (ko) |
DE (1) | DE602004026903D1 (ko) |
DK (1) | DK1678162T3 (ko) |
ES (1) | ES2342290T3 (ko) |
HK (1) | HK1096399A1 (ko) |
IL (1) | IL174665A (ko) |
MX (1) | MXPA06003803A (ko) |
NO (1) | NO336127B1 (ko) |
NZ (1) | NZ546257A (ko) |
PL (1) | PL1678162T3 (ko) |
PT (1) | PT1678162E (ko) |
RU (1) | RU2317985C1 (ko) |
SI (1) | SI1678162T1 (ko) |
WO (1) | WO2005033097A1 (ko) |
ZA (1) | ZA200603538B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140076979A (ko) * | 2012-12-13 | 2014-06-23 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0700773D0 (en) * | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
CA2679659C (en) * | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
BR112014028954A2 (pt) | 2012-05-21 | 2017-07-18 | Novartis Ag | amidas de n-piridinila substituídas no anel como inibidores da quinase |
CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
KR20150135110A (ko) * | 2014-05-23 | 2015-12-02 | 한미정밀화학주식회사 | p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물 |
CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
TWI715636B (zh) | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
EP3773581A4 (en) * | 2018-04-13 | 2021-12-29 | Athenex Therapeutics Limited | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma |
EP3893867A1 (en) | 2018-12-14 | 2021-10-20 | Athenex HK Innovative Limited | Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer |
CN113631166A (zh) * | 2018-12-14 | 2021-11-09 | 慧源香港创新有限公司 | 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合 |
WO2020168144A1 (en) | 2019-02-14 | 2020-08-20 | Teva Pharmaceuticals International Gmbh | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt |
WO2020230037A1 (en) * | 2019-05-13 | 2020-11-19 | Dr. Reddy's Laboratories Limited | Alternate process for the preparation of encequidar |
WO2021044350A1 (en) * | 2019-09-04 | 2021-03-11 | Dr. Reddy’S Laboratories Limited | Solid forms of encequidar mesylate and processes thereof |
WO2022011221A1 (en) | 2020-07-10 | 2022-01-13 | Teva Czech Industries S.R.O | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt |
IL301516A (en) | 2020-10-07 | 2023-05-01 | Athenex Inc | Acetamido-phenyltetrazol derivatives and methods of using them |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2074867T3 (es) | 1990-11-06 | 1995-09-16 | Pfizer | Derivados de quinazolina para potenciar la actividad antitumoral. |
JP3223193B2 (ja) * | 1991-08-09 | 2001-10-29 | 株式会社日清製粉グループ本社 | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 |
ES2103479T3 (es) | 1992-07-10 | 1997-09-16 | Glaxo Lab Sa | Derivados de anilida. |
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
EP1256341A4 (en) * | 2000-02-15 | 2004-12-08 | Teijin Ltd | ANTI-CANCER MEDICINAL PRODUCT COMPRISING AN ANTHRANILIC ACID DERIVATIVE AS AN ACTIVE INGREDIENT |
DE60326341D1 (de) | 2002-05-14 | 2009-04-09 | Xenova Ltd | Verfahren zur herstellung von anthranilsäurederivat-hydrat |
KR100580743B1 (ko) | 2003-10-08 | 2006-05-15 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법 |
-
2003
- 2003-10-07 KR KR1020030069582A patent/KR100557093B1/ko active IP Right Grant
-
2004
- 2004-10-06 CA CA002541301A patent/CA2541301C/en active Active
- 2004-10-06 PT PT04774778T patent/PT1678162E/pt unknown
- 2004-10-06 SI SI200431434T patent/SI1678162T1/sl unknown
- 2004-10-06 MX MXPA06003803A patent/MXPA06003803A/es active IP Right Grant
- 2004-10-06 RU RU2006114427/04A patent/RU2317985C1/ru active
- 2004-10-06 US US10/574,098 patent/US7625926B2/en active Active
- 2004-10-06 AU AU2004277475A patent/AU2004277475B2/en active Active
- 2004-10-06 PL PL04774778T patent/PL1678162T3/pl unknown
- 2004-10-06 CN CN2004800293562A patent/CN1863795B/zh active Active
- 2004-10-06 WO PCT/KR2004/002550 patent/WO2005033097A1/en active IP Right Grant
- 2004-10-06 DE DE602004026903T patent/DE602004026903D1/de active Active
- 2004-10-06 JP JP2006532094A patent/JP4481992B2/ja active Active
- 2004-10-06 ES ES04774778T patent/ES2342290T3/es active Active
- 2004-10-06 DK DK04774778.7T patent/DK1678162T3/da active
- 2004-10-06 BR BRPI0415053A patent/BRPI0415053B8/pt active IP Right Grant
- 2004-10-06 EP EP04774778A patent/EP1678162B1/en active Active
- 2004-10-06 AT AT04774778T patent/ATE466008T1/de active
- 2004-10-06 NZ NZ546257A patent/NZ546257A/en unknown
-
2006
- 2006-03-30 IL IL174665A patent/IL174665A/en active IP Right Grant
- 2006-05-04 ZA ZA200603538A patent/ZA200603538B/xx unknown
- 2006-05-05 NO NO20062019A patent/NO336127B1/no unknown
-
2007
- 2007-04-13 HK HK07103870.2A patent/HK1096399A1/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140076979A (ko) * | 2012-12-13 | 2014-06-23 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100557093B1 (ko) | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 | |
JP6436205B2 (ja) | キノリン誘導体 | |
KR101727757B1 (ko) | 키나아제 억제제 화합물 | |
KR20020068388A (ko) | 술폰아미드 함유 복소환 화합물 | |
EP1945612A2 (en) | Heterocyclic compounds as pstat3/il-6 inhibitors | |
AU2014301295A1 (en) | Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors | |
JP5892550B2 (ja) | 縮合イミダゾール誘導体 | |
JP7395807B2 (ja) | アミド類化合物の調製方法及びその医薬分野の使用 | |
CN106117182B (zh) | 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用 | |
CN109666022B (zh) | 三氮唑衍生物及其制备方法和用途 | |
WO2023284159A1 (zh) | 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用 | |
WO2023249105A1 (ja) | 薬剤性心筋障害の治療剤又は予防剤 | |
JP2837318B2 (ja) | アンジオテンシンii拮抗性ピリジン誘導体 | |
EP4373485A1 (en) | Cxcr4 modulators and uses related thereto | |
KR20240066906A (ko) | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120313 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131231 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141215 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161216 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181218 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 15 |